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Melanoma cells possess a special biochemical pathway 
for the conversion of L-dopa to melanin. Selective incor-
poration of exogenou s L-dopa into melanoma cells in 
vivo has been limited by extensive decarboxylation to 
dopamine. Pretreatment of animals bearing the S-91 
Cloudman or ACI melanomas with Ro4-4602, a potent 
dopa decarboxylase inhibitor limited incorporation of 
label into adrenal tissue and enhanced entry oflabel into 
tumor. Six hours following pretreatment, the ratio of 
tumor to adrenal specific activities was altered from 0.25 
to 1.5 for the S-91 melanoma and 0.68 to 1.99 for the ACI 
melanoma indicating diversion of metabolism away from 
catecholamine formation. The possibility of a selective 
diagnostic and/or therapeutic approach is proposed. 
Malignant melanoma is a therapeutically resistant tumor 
that possesses a special bioch emical pathway for the conversion 
of L-3,4-dihydroxyphenylalanine (L-dopa) to th e biopigment 
melanin [1]. The biosynthesis of melanin is catalyzed by the 
enzym e tyrosinase, which is restricted to normal and maHgnant 
melanocytes. Attempts to utilize this pathway for th e design of 
specific chemotherapeutic or diagnostic agents have fo cused on 
the selective incorporation of melanin precursors. Recently, we 
have demonstrated the highly selective, temperature-depend-
ent incorporation of L-dopa by pigmented melanoma cells in 
vitro and have restudied incorporation in vivo [2]. 
Three previous reports have examined the partition of L-
dopa in animals bearing melanoma with conllicting results. 
Blois and Kallman showed a highly selective incorporation of 
radiolabeled L-dopa into a spontaneously arising mmine mel-
anoma [3]. Hempel and Deimel, utilizing the Harding-Passey 
model, demonstrated extensive incorporation into tumor but 
there was even greater incorporation into the adrenal medulla 
[ 4]. Finally, Meier, Beierwaltes and Counsell were able to show 
selective incorportation into the Fortner hamster melanoma 
but not into B-16 tumor [5]. In each study, it was apparent that 
decarboxylation of precursor L-dopa to dopamine and diversion 
to catecholamine biosynthesis was a major limitation since 
incorporation of label into adrenal medulla was always exten-
SIVe. 
Recent understanding of the human clinical pharmacology of 
L-dopa confirms that of an administered dose 69% is diver ted 
to catecholamine biosynthesis, 1% excreted unchanged, 10% 
excreted as metabolites of L-dopa and 20% of the label not 
recovered [6]. Potent inhibitors of the initial decarboxylation 
by the enzyme aromatic L-amino acid decarboxylase (dopa 
decarboxylase) have been developed for use in conjunction with 
L-dopa in the therapy of Parkinson's disease, wher e their use 
permits a large reduction in required therapeutic dose of L-
dopa [7,8]. 
We report om results of the effect of a recently available 
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inhibitor of dopa decarboxylase on the t issue distribu tion of 
radiolabeled L-dopa in experimental melanoma. One of t hese 
inhibitors, Ro4-4602, causes a ma1·ked inhibition of incorpora-
tion of la bel into the adrenal medulla with a conco mitant 
enhancement of tumor incorporation in the ACI and S-91 
Cloudman transplantable melanomas. 
MATERIALS AND METHODS 
Chemical Agents 
L-3,4-dihydroxyphenylalanine (L-dopa) was obtained from Sigma 
Chemical Co., St. Louis, Mo. Ro4-4602 (W-(DL-seryl) -W-(2,3,4-trihy-
droxybenzyl) hydrazine was a gift from Hoffman LaRoche Co., Nutley, 
New Jersey. Uniformly radiolabeled 3H-L-dopa (specific activity 11 
Ci/mmole) was obtained from New England Nuclear Co., Boston, Mass. 
All other chemicals were reagent grade and used without further 
purification. 
Tumors 
The origin and maintenance of the cell lines has been described [2]. 
S-91A refers to a pigmented clone of Cloudman melanoma while S-91B 
refers to a hypomelanotic clone. The ACI rat melanoma, a heavily 
pigmented tumor, was from the Mason Reseru·ch Laboratory, Worces-
ter, Mass. Tumors were maintain~d by serial subcutaneous implanta-
tion of tumor cells following standard National Cancer Institute pro-
tocols [9]. Experiments were conducted on tumors when they were 
approximately 1 em in diameter. 
T issue Radioactivity 
All injections were given intraperitoneally in normal saline. L-dopa 
was administered at a dose of 2.5 mg/ kg with 20 ILCi for rats and 25 
mg/ kg with 10 /LCi for mice. Ro4-4602 was administered at a dose of 
250 mg/ kg in rat experiments and 500 mg/ kg in mouse experiments, 1 
hr prior to L-dopa. 
Animals were sacrified by cervical dislocation. Serum samples were 
obtained by retro-orbital bleeding. 20-30 mg samples of tissue were 
obtained 6 hr following injections and transferred directly to pre-
weighed scintillation vials. Three samples of each tissue were removed 
from each animal. The use of the rat melanoma permitted the dissection 
of the adrenal medulla away from the remainder of the gland. 0.5 ml of 
Protosol (New England Nuclear, Boston, Mass.) was added and samples 
were heated at 50°C for 12 hr. 10 ml of scintillation fluid (Aquasol, New 
England Nuclear Co.) were added and samples were counted on a 
Beckman LS-335 scintillation counter. Quenching was corrected by 
addition of an internal toluene standard. 
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RESULTS 
Figure 1 shows the tissue distribution of L-dopa and dopa-
mine in normal mice (BDF1 , 6-8 weeks of age, Jackson Labo-
ratory, Bar Ha1·bor, Maine) at 24 hr. Dopamine is specifically 
incorporated into the adrenal gland; L-dopa without decarbox-
ylase inhibition, displays a pattern similar to dopamine reflect-
ing its extensive conversion to the latter compound. Pretreat-
ment with Ro4-4602 effects a profound alteration in distribu-
tion. Adrenal incorporation is minimal, while the predominantly 
renal excretion ofmetaboHtes is reflected in high kidney specific 
activity. T his activity was equal to that observed in a sample of 
mine taken at the time of sacrifice, thus suggesting its non par-
enchymal location. The adrenal radioactivity, although repre-
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FIG 1. Tissue distribution of radioactivity 24 hr fo llowing administra-
tion of labeled precursor. L (liver), S (spleen) , K (kidney), A (adrena l) , 
Sr (serum) . Values represent mean± S.E.M. for 3 animals/group. 
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FIG 2. Effect of decarboxylase inhibit ion on tissue distribution of 
radioactivity. Values represent mean ± S.E.M. for 3 animals/ group. 
ACI melanotic melanoma, S-91A melanotic melanoma. L (liver), S 
(spleen), A (adrenal) , Sr (serum), Br (brain), T (tumor). 
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FIG 3. Effect of decarboxylase inhibit ion on t issue distribution of 
radioactivity in S-91B hypomelanotic melanoma. Values represent 
mean ± S.E.M. for 3 animals/group. L (liver), S (spleen) , A (adrenal), 
Sr (serum) , Br (brain), T (tumor). 
senting only a small fraction of the overall administered dose is 
t h erefore a convenient biologic index of the degree to which L-
dopa has been converted to dopamine. 
Figure 2 depicts the effect of decarboxylase inhibition in both 
t h e ACI and S-91 melanotic tumors, as measw-ed 6 h.r after 
a dministration. Since adrenal radioactivity is stable over several 
days, 24 hr is the optimum time at which to demonstrate the 
e ffects of decru·boxylase inhibit ion on ad.I·enal incorporation. 
We have found however, that 6 luis the t ime at which tumor 
radioactivity is maximal. This result is to be expected since 
melanin is a continuously growing polym er that must lose label 
as it grows. The difference in time at which the tissues were 
sampled accounts for the elevated serum activi ty in Fig 2 as 
compared to Fig 1 and also for the elevated ad.I·enal activi ty, 
s ince whole t issue was sampled including extracellular fluid. 
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In each case, the effect of decarboxylase inhibit ion is most 
apparent when one examines the ratio of tumor/adrenal activ-
ity. For the ACI melanoma, the ratio was altered from 0.68 to 
1.99 with pretreatment. In the S-91 melanotic melanoma, the 
tumor/ ad.I·enal ratio for controls was 0.25 while animals treated 
with the decarboxylase inhibitor showed a ratio of 1.5. 
The hypomelanotic melanoma S-91B, shows much less in-
corporation oflabel (Fig 3). Fw-thermore, although serum levels 
are enhanced by decarboxylase inhibition there is no specific 
increase found in the tumor. In vitro, S-91B incorporates about 
one-tenth of the label that S-91A incorporates [2]. 
DISCUSSION 
The role of L-dopa as a precw-sor of catecholamine biosyn-
thesis has severely limited potential selective chemotherapeutic 
or diagnostic intervention. It is apparent from ow- experiments 
that administering L-dopa in the presence of a potent decar-
boxylase inhibitor, like Ro4-4602, results in higher serum levels 
and enhancement of incorporation into melanoma. The major 
diversion of label into adrenal t issue that was apparent in all 
previous in vivo studies of L-dopa incorporation by melanoma 
could be largely obviated. No attempt was made in these studies 
to maximize L-dopa incorporation into tumor but rather we 
attempted to use conditions similar to those of previous studies 
to afford a basis for meaningful comparison. 
The possibility of selective localization of radiolabeled com-
pounds for tissue identification has been a useful one with the 
principle example being that of ad.I·enal gland scanning with 
13 11-iodocholesterol [10]. This technique is completely depend-
ent on biologic selectivity in concentration of precursor. Decar-
boxylase inhibition may afford the possibility of a similru· op-
portunity with L-dopa and melanoma. T he proposal of Hempel 
and Dein1el, therefore, may now be reexplored [ 4]. They ini-
tially suggested the use of radiolabeled L-dopa for the radio-
therapy of melanoma. T hey concluded from the results of their 
studies, however, that the concentration of activity in the 
melanoma was insufficien t. 
Finally, we have reported that L-dopa is selectively toxic to 
pigmented melanoma cells in vitro [11 ,12]. Furthermore, we 
have shown that the methyl ester of L-dopa possesses signifi-
cant antitumor activity against B-16 melanoma in vivo and that 
this activity is enhanced by pretreatment with a dopa decar-
boxylase inhibitor [13]. Presumably, decarboxylase inhibition 
as demonstrated here does afford greater in vivo cytotoxic 
concentration. 
We are g1·ateful to Drs. Emil Frei III, and T homas B. Fitzpatrick for 
helpful discussions and advice throughout this investigation. 
REFERENCES 
1. Luce JK, M cBride CM, Frei III E: Melanoma. Cancer Medicine, 
First edition. Edited by JF Holland and E Frei III. Philadelphia, 
Pennsylvania, Lea and Febiger, 1974, pp 1823-1844 . 
2. Wick MM, Frei III E: Selective incorporation of L-dopa-3H by 
melanoma in vitro. Cancer Res 37:2123-2125, 1977 
3. Blois MS, Kallman, RF: T he incorporation of "C from 3,4-dihy-
d..roxyphenylalanine-2-"C into the melanin of mouse melanomas. 
Cancer Res 24 :863-868, 1964 
4. Hempel K, Deimel M: Studies on controlled radiotherapy of mel-
anoma and on the chromaffin system by selective "H incorpora-
t ion after administration of "H-labeled dopa. Strahlentherapie 
121:22-44, 1963 
5. Meier MM , Beierwaltes WH, Counsell RE: Radioactivity from 
labeled precursor of melanin in mice and hamsters with mela-
noma. Cancer Res 27:1354-1359, 1967 
6. Goodall MC, Alton H: Metabolism of L-dopa in human subjects. 
Biochem Pharmacol 21:2401-2408, 1972 
7. BUJ·khard WP, Gey KF, P letscher A: Inhibi tion of decarboxylase or 
360 WICK, KRAMER, AND GORMAN 
aromatic amino acids by 2,3,4-trihydroxybenzylhydrazine and its 
seryl derivative. Arch Biochem Biopys 107:187-196, 1964 
8. Lotti V J, Porter CC: J Pharmacol Exp Ther 172:406-415, 1970 
9. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, 
Abbott BJ: Protocols for screening chemical agents and natural 
products against animal tumors and other biological systems. 
Third edition. Cancer Chemotherap Rep part 3, No.2, 1972 
10. Lieberman LM, Beierwaltes WH, Conn JW, Ansari A, Nishiyama 
Vol. 70, No. 6 
H: Diagnosis of adrenal glands with '" 'I-19-iodocholesterol. New 
Eng! J Med 285:1387-1393, 1971 
11. Wick MM, Byers L, Frei III E: Selective toxicity of L-dopa for 
melanoma cells in vitro. Science 197:468-469, 1977 
12. Wick MM, Byers L: Selective toxicity of L-dopa for melanoma in 
vitro. Clin Res 25:413A, 1977 
13. Wick MM: L-dopa methyl ester-A new antitumor agent. Nature 
269:512-513, 1977 
